BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset First clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
